Niels van de Donk, MD, PhD, Discusses MajesTEC-1 Follow-Up Data on Teclistamab in Multiple Myeloma
By Cecilia Brown, Niels van de Donk, MD, PhD - Last Updated: September 5, 2023Niels van de Donk, MD, PhD, of the Amsterdam University Medical Center, discusses his presentation on longer-term follow-up data from the MajesTEC-1 study during the 2023 American Society of Clinical Oncology Annual Meeting.
Advertisement
The study evaluated the bispecific antibody teclistamab in patients with relapsed or refractory multiple myeloma. In this video, Dr. van de Donk speaks about what he sees as the most clinically significant results from the extended follow-up study, the real-world implications of the results, as well as remaining questions and next steps.
Post Tags:MyelomaASCO23
Advertisement
Related Posts
The ASCO Association Board Chair has written letters to the new heads of the CMS, FDA, and NIH.
Dr. Parekh discussed the promising future of trispecifics, the group of patients with the largest unmet need, and more.
Investigators assert clinical trial design features may have contributed to this antibody-drug conjugate's loss of approvals.
Samir Parekh, MD, Appointed Director of the Center of Excellence for Multiple Myeloma at Mount Sinai
Dr. Parekh’s laboratory focuses on developing personalized treatment strategies for patients with multiple myeloma.
Seta Degann, MD, resident physician at George Washington University, described the challenges of diagnosing younger patients.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.